18 Biggest Mid-Day Gainers For Wednesday - BeiGene (NASDAQ:BGNE), Axon Enterprise (NASDAQ:AXON)

RYB Education, Inc. RYB shares rose 41 percent to $26.10. RYB Education prices IPO at $18.50 per share.
iCAD Inc ICAD shares gained 25.6 percent to $4.37.
Overstock.com, Inc. OSTK shares rose 18 percent to $27.65 following news from the company's tZERO unit of joint venture with RenGen and Argon for the launch of Alternative Trading System used for security tokens issued by ICO in compliance with SEC and FINRA regulations.
Remark Holdings, Inc. MARK shares surged 16.9 percent to $4.15 after the company reported a $1 million+ contract to provide facial and object recognition to a Chinese government owned business.
Veru Inc VERU shares rose 15.1 percent to $2.88.
Beigene Ltd (ADR) BGNE shares climbed 13.5 percent to $99.29.
HubSpot Inc HUBS jumped 12 percent to $80.75 as the company raised its Q3 outlook.
Cempra Inc CEMP shares gained 10.8 percent to $3.38 after declining 3.17 percent on Tuesday.
Axovant Sciences Ltd AXON surged 10.8 percent to $7.00 after dipping 73.90 percent on Tuesday.
Determine Inc DTRM shares rose 10.8 percent to $2.26.
KEMET Corporation KEM shares climbed 9.2 percent to $21.19. S&P Dow Jones Indices reported that KEMET will join S&P SmallCap 600.
Audentes Therapeutics Inc BOLD shares rose 9.9 percent to $32.38 as the company disclosed that it has been granted Fast Track and Rare Pediatric Disease designations for AT132.
Lumentum Holdings Inc LITE gained 8.2 percent to $54.97. MKM Partners upgraded Lumentum from Neutral to Buy.
Micron Technology, Inc. MU climbed 7.8 percent to $36.83 after the company reported stronger-than-expected results for its fourth quarter.
China Auto Logistics Inc CALI shares gained 6.2 percent to $2.22 after gaining 0.48 percent on Tuesday..
Twilio Inc TWLO gained 5.5 percent to $29.03 following news that Amazon's AWS Pinpoint launched 2-way text messaging.
Zealand Pharma A/S ZEAL shares rose 5.1 percent to $18.98. Goldman Sachs initiated coverage on Zealand Pharma with a Buy rating.
Cascadian Therapeutics Inc (USA) CASC shares rose 4 percent to $4.02 after the company disclosed that it has been granted Orphan Drug Designation for Tucatinib for the treatment of colorectal cancer.

Market News and Data brought to you by Benzinga APIs